PMID: 18723960Aug 30, 2008Paper

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections

Indian Journal of Pathology & Microbiology
Ami Y VaraiyaPallavi N Bhalekar

Abstract

Diabetic foot lesions are a major medical, social, and economic problem and are the leading cause of hospitalization for patients with diabetes, worldwide. ESBL-producing bacteria may not be detectable by routine disc diffusion susceptibility test, leading to inappropriate use of antibiotics and treatment failure. There is not much information on ESBL-producing organisms causing diabetic foot infection. An attempt was therefore made to study the ESBL-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot patients with type 2 diabetes mellitus. A total of 134 isolates of E. coli and K. pneumoniae were obtained from tissue, pus swab, and wound swab samples from diabetic foot ulcers submitted for routine microbiological analysis during the period January to December 2005 from patients with diabetic foot infections who had type 2 diabetes mellitus, attending S. L. Raheja Hospital. The above isolates were tested for antimicrobial susceptibility by disc diffusion technique according to clinical and laboratory standards institute (CLSI) guidelines. The screening for ESBL production was done by phenotypic confirmatory test using ceftazidime disc in the presence and absence of clavulanic acid as recommended by CLSI. Among...Continue Reading

Citations

Aug 25, 2009·Current Infectious Disease Reports·Sandra Bliss Nelson
Jul 14, 2010·Foodborne Pathogens and Disease·Spencer HeringaXiuping Jiang
Jan 14, 2011·Plastic and Reconstructive Surgery·Nalini RaoBenjamin A Lipsky
Nov 16, 2010·Expert Review of Anti-infective Therapy·Mark A Kosinski, Benjamin A Lipsky
Feb 9, 2016·Laboratory Investigation; a Journal of Technical Methods and Pathology·Rachel CromptonMatthew J Hardman
Oct 16, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ilker UçkayBenjamin A Lipsky
Feb 16, 2012·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Akhil K SethKai P Leung
Feb 1, 2012·Diabetes/metabolism Research and Reviews·B A LipskyW J Jeffcoate
Dec 4, 2009·Expert Opinion on Pharmacotherapy·I ByrenB A Lipsky
Apr 7, 2011·Scandinavian Journal of Infectious Diseases·Jessie S GlasserClinton K Murray
Oct 9, 2021·Frontiers in Medicine·Wei ChaiXuezhi Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.